Page last updated: 2024-11-05

2,4,6-trichlorophenyl 4-nitrophenyl ether

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

2,4,6-trichlorophenyl 4-nitrophenyl ether: structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID15788
CHEMBL ID4520017
CHEBI ID3620
SCHEMBL ID39135
MeSH IDM0055915

Synonyms (43)

Synonym
BIDD:ER0062
chlornitrofen (cnp)
unii-1nmn2my1cw
1nmn2my1cw ,
2',4',6'-trichloro-4-nitrobiphenyl ether
p-nitrophenyl 2,4,6-trichlorophenyl ether
ccris 7156
einecs 217-407-6
4-nitrophenyl 2,4,6-trichlorophenyl ether
brn 1890443
mo 338
mc 1478
ether, p-nitrophenyl 2,4,6-trichlorophenyl
mc 338
chlornitrofen [iso]
cnp 1032
2,4,6-trichloro-4'-nitrodiphenyl ether
benzene, 1,3,5-trichloro-2-(4-nitrophenoxy)-
OPREA1_424535
mc-338
1836-77-7
chlornitrofen
2,4,6-trichlorophenyl 4-nitrophenyl ether
CNP ,
1,3,5-trichloro-2-(4-nitrophenoxy)benzene
1,3,5-tris(chloranyl)-2-(4-nitrophenoxy)benzene
A812805
AKOS015903305
trichlorophenyl-4-nitrophenyl ether, 2,4,6-
chlornitrofen [mi]
1,3,5-trichlor-2-(4-nitrophenoxy)benzol
mo-338
2,4,6-trichlorophenyl-4'-nitrophenyl ether
SCHEMBL39135
CHEBI:3620
1-nitro-4-(2,4,6-trichlorophenoxy)benzene
2,4,6-trichlorophenyl p-nitrophenyl ether
diphenyl ether, 2,4,6-trichloro-4'-nitro
DTXSID0041775
chlornitrofen, analytical standard
CHEMBL4520017
mfcd00210255
Q11299853
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
EC 1.3.3.4 (protoporphyrinogen oxidase) inhibitorAn EC 1.3.3.* (oxidoreductase acting on donor CH-CH group with oxygen as acceptor) inhibitor that interferes with the action of protoporphyrinogen oxidase (EC 1.3.3.4).
herbicideA substance used to destroy plant pests.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (3)

ClassDescription
aromatic etherAny ether in which the oxygen is attached to at least one aryl substituent.
chlorobenzenesAny organochlorine compound containing a benzene ring which is substituted by one or more chlorines.
C-nitro compoundA nitro compound having the nitro group (-NO2) attached to a carbon atom.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (2)

Assay IDTitleYearJournalArticle
AID1640019Luciferase/luciferin-expressing antifolate-resistant parasites were used to infect a culture of HepG2 cells that were pre-incubated with compounds. Infected hepatocytes emit light due to the luciferase reaction. Assay results are presented as the percent 2018Science (New York, N.Y.), 12-07, Volume: 362, Issue:6419
Open-source discovery of chemical leads for next-generation chemoprotective antimalarials.
AID1640018Luciferase/luciferin-expressing antifolate-resistant parasites were used to infect a culture of HepG2 cells that were pre-incubated with compounds. Infected hepatocytes emit light due to the luciferase reaction. Assay results are presented as the percent 2018Science (New York, N.Y.), 12-07, Volume: 362, Issue:6419
Open-source discovery of chemical leads for next-generation chemoprotective antimalarials.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (28)

TimeframeStudies, This Drug (%)All Drugs %
pre-19908 (28.57)18.7374
1990's8 (28.57)18.2507
2000's10 (35.71)29.6817
2010's2 (7.14)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 10.97

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index10.97 (24.57)
Research Supply Index3.37 (2.92)
Research Growth Index4.33 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (10.97)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (3.57%)6.00%
Case Studies1 (3.57%)4.05%
Observational0 (0.00%)0.25%
Other26 (92.86%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]